Introduction
Neurodegenerative diseases (NDs) are characterized by the progressive loss of specific neuronal populations, resulting in motor and cognitive impairments [1]. Among these, Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD) are common types of ND. The development of various NDs is influenced by ageing, genetic susceptibilities and environmental factors [2]. In addition, emerging evidence reveals that peripheral factors play vital roles in the development of NDs [3,4]. The multifaceted aetiologies and origins of NDs suggest that it is insufficient to focus on the end pathology within the central nervous system to prevent the onset and progression of NDs.
The human gastrointestinal tract hosts trillions of microorganisms collectively known as the gut microbiome. Recent substantial evidence underscores the pivotal role of the gut microbiome in maintaining general health, especially health in the central nervous system [5,6]. The gut microbiome is involved in the regulation of mental health, social behaviour, cognition function, etc., earning it the nickname “the second brain” of humans [5,6,7]. The composition of gut microbiome undergoes changes throughout the lifespan and is constantly influenced by factors such as ageing, genetic variants and environmental factors [8]. Notably, the gut microbiome has the capacity to regulate brain functions through the immunological pathway, the vagus nerve, the circulatory pathway, the hypothalamic-pituitary-adrenal axis, and the lymphatic and glymphatic circulation [9,10] (Fig. 1). Many researchers believe that the crosstalk between the gut microbiome and the brain is crucial in the development of NDs, suggesting that modifying the gut microbiome holds promise as a therapeutic avenue for NDs [11,12,13].
Fig. 1 Overview of the gut microbiome-brain axis. Communications between the gut microbiome and the central nervous system (CNS) involve circulatory, immunological, vagus nerve, lymphatic and glymphatic, and neuro-endocrine (hypothalamic-pituitary-adrenal [HPA] axis) pathways. Gut microbes, their products (pathogen-associated molecular pattern [PAMPs] and extracellular vesicles) and metabolites, and gut neurotransmitters and hormones secreted by enteroendocrine cells, can transport to the CNS via peripheral circulation and impaired blood-brain barrier; they also interact with the host immune system and affect the CNS via blood circulation or lymphatic and glymphatic system. In addition, microbes and bacterial DNA can also translocate into the mesenteric lymphatic nodes. The vagus nerve transmits neural signals from the CNS to the gut, and also transports gut signals (activated by metabolites or neurotransmitters and hormones secreted by enteroendocrine cells) or gut microbiome-derived products like extracellular vesicles to the CNS. The HPA axis is a major neuro-endocrine system responding to stress by the release of cortisol from the adrenal cortex, which subsequently regulates the gut immune system and influences the gut microbiome composition. In turn, the gut microbiome can activate the HPA axis. EC enteroendocrine cell, IL interleukin, LPS lipopolysaccharide, SCFAs short-chain fatty acids, Th T helper cell, TNF-α tumour necrosis factor-α |
The gut microbiome-brain axis in NDs has been discussed by several researchers in the past years [14,15,16]. In this review, we aim to summarize updated evidence implicating the critical role of the gut microbiome in the development of NDs and to highlight novel therapeutic opportunities that target the gut microbiome.
Roles of the gut microbiome in NDs
Numerous pieces of evidence have shed light on the interactions between the gut and the brain in NDs. It has been reported that AD patients have a higher incidence of significant upper and lower gastrointestinal events, as nearly 80% of PD and 60% of ALS patients suffer from constipation [17,18,19]. HD patients are usually complicated with weight loss, gastritis, extended colonic transit times and nutritional deficiencies [20]. The gut microbiome has been proven to be a critical modulator of this gut-brain axis. Here, we will provide a brief overview of the gut microbiome-brain axis in NDs.
Correlations between gut microbiome and NDs
AD
A meta-analysis covering 378 healthy controls and 427 AD patients from 11 studies reported increased abundance of Proteobacteria, Bifidobacterium and Phascolarctobacterium and decreased abundance of Firmicutes, Clostridiaceae, Lachnospiraceae and Rikenellaceae in AD patients [23]. Recent studies have shown that the gut microbiome profiles are distinct between preclinical AD patients and healthy individuals, and the gut microbiome profiles and specific taxa are correlated with amyloid-β (Aβ) and tau pathological biomarkers in the brain and the plasma Aβ42/Aβ40 ratio, suggesting that changes of the gut microbiome may occur early in the disease process before neuronal injury [24,25]. Furthermore, injection of Aβ into the lateral ventricle can cause cognitive impairments and inhibit the vagus nerve-mediated cholinergic anti-inflammatory pathway. This inhibition is accomplished by reducing the expression of M1-type acetylcholine receptors in the mouse brain [26]. Consequently, it results in decreased acetylcholine secretion and reduced α7 acetylcholine receptor levels in gut macrophages [26]. These changes shift the macrophages towards pro-inflammatory phenotypes, ultimately causing damage to enteric neurons and the gut mucosal barrier, and accelerating amyloidogenic pathways and gut microbiome dysbiosis [26]. These data suggest that Aβ in the brain has a direct effect on gut homeostasis and gut microbiome profiles.
The altered gut microbiome will further exacerbate the progression of AD. Transplantation of the gut microbiome derived from AD patients or mice (5×FAD) can worsen Aβ deposition, neuroinflammation and cognitive impairments in recipient mice compared to transplantation of the gut microbiome from healthy donors [11,27,28]. In addition, the deposition of Aβ, tau aggregates and cognitive impairments can be ameliorated by eliminating the gut microbiome in AD (APP/PS1, Tau/APOE4) mice through germ-free conditions or administration of antibiotics [29,30,31]. These studies have revealed that the gut microbiome and its products and metabolites play a significant role in altering the phenotypes and functions of microglia, thereby affecting Aβ deposition in the brains of AD patients.
PD
Increased abundance of Akkermansia, Bifidobacterium and Lactobacillus as well as reduced abundance of Roseburia, Faecalibacterium, Blautia and Lachnospiraceae have been mostly reported in PD patients and are strongly associated with the duration, onset time, and motor and nonmotor deficits of PD [32,33]. Recently, Huang et al. investigated the gut microbiome across early PD, REM sleep behaviour disorder (RBD, prodromal PD), first-degree relatives of RBD (RBD-FDR, even earlier prodromal stage and younger population), and healthy controls. They found that the gut microbiome composition in RBD patients was altered to be close to early PD, with depletion of butyrate-producing bacteria and enrichment of Collinsella, Desulfovibrio, and Oscillospiraceae UCG-005. The RBD-FDR patients also showed the RBD/PD-like microbial alterations, including increased abundance of Collinsella and depletion of butyrate-producing bacteria. This evidence suggests that gut microbiome dysbiosis occurs at the early stage of PD and can be used to predict the onset of RBD and PD [34].
On the other hand, the gut microbiome can be a modifier in the progression of PD. Germ-free PD (α-synuclein-overexpressing) mice show improved motor and gastrointestinal functions and reduced insoluble α-synuclein aggregates in the brain compared to specific pathogen-free (SPF) PD mice. In addition, postnatal colonization of the germ-free PD mice recapitulated the genotype effects observed in SPF mice [35]. Furthermore, aggravation of microglial activation caused by gut microbiome-derived short-chain fatty acids (SCFAs) may lead to increased α-synuclein aggregates in PD mice [35].
ALS
Different cohorts of ALS patients have shown increased abundance of Bacteroidetes and Enterobacteriaceae and decreased abundance of Lachnospiraceae [36]. In addition, a lower ratio of Firmicutes/Bacteroidetes was found in ALS patients with cognitive impairments in comparison to those with normal cognition [37]. Administration of low-dose antibiotics exacerbates motor deficits and reduces survival in the ALS (SOD1G93A) mouse model. This effect may be attributed to the downregulation of homeostatic genes and upregulation of ND genes in spinal cord microglia in the ALS mice [38].
HD
Wasser et al. investigated the gut microbiome in HD gene expansion carriers (HDGECs) and their healthy controls, and found lower abundance of Firmicutes, Lachnospiraceae and Akkermansiaceae in HDGEC males [22]. Du et al. revealed that the HD patients have increased α-diversity and β-diversity of gut microbiota compared to healthy controls. In addition, the abundance of genus Intestinimonas is positively correlated with plasma levels of interleukin (IL)-4, and the abundance of genus Bilophila is negatively correlated with proinflammatory IL-6 levels, indicating that alterations in faecal microbiota may interact with the immune responses in HD patients [39]. In addition, it has been reported that faecal microbiome transplantation (FMT) from healthy (wild-type) into HD (R6/1) mice with antibiotics pretreatment significantly improves the cognitive functions only in females, which might be due to the microbial instability, acetate imbalance and gut immune profiles in male HD mice [40].
In conclusion, the gut microbiome-brain axis is bidirectional and complex, making it difficult to identify cause and effect between gut dysbiosis and neurodegeneration. The alterations in the gut microbiome in NDs are not always consistent across studies, possibly due in part to geographical, racial, or lifestyle differences. However, a common alteration seems to be the loss of butyrate-producing bacteria, such as Lachnospiraceae in AD, PD, ALS and HD, and Roseburia and Faecalibacterium in PD. The abundance of Lachnospiraceae is involved in ageing and the regulation of inflammation. It has been found that Rehmannia glutinosa polysaccharides can enhance the antioxidant enzyme system and delay ageing in Caenorhabditis elegans, which may be associated with increased abundance of Lachnospiraceae NK4B4 group and regulation of amino acid metabolism and energy cycling [41]. FMT from young mice rejuvenates the aged hematopoietic stem cells and mitigates inflammatory signals by increasing Lachnospiraceae and tryptophan-associated metabolites [42]. Lachnospiraceae also contributes to intestinal protection through enhancement of the L-lysine fermentation pathway in a mouse model of sepsis [43]. In addition, oral FMT leads to enrichment of Lachnospiraceae and butyrate, and suppresses liver ferroptosis via activation of the adenosine 5’-monophosphate-activated protein kinase/P62/nuclear factor erythroid 2-related factor 2 signalling and induction of mitophagy, subsequently mitigating the acetaminophen-induced liver injury in mice [44].
Oxidative stress is considered a part of the ageing process and is also involved in the development and progression of NDs [10]. A cross-sectional study has revealed that patients with NDs display elevated serum levels of soluble NADPH oxidase 2-dp, H2O2 and lipopolysaccharide (LPS) (which is derived from gram-negative bacteria). Furthermore, there is a positive correlation between the serum LPS and serum zonulin (a maker of gut permeability) levels, suggesting the involvement of gut barrier impairment and bacteria translocation in the elevation of oxidative stress in NDs [45]. It has been found that both commensal and pathogenic bacteria in gut can alter the oxidative stress by regulating mitochondrial activity [46]. Lactobacillus and Bifidobacterium are capable of converting nitrate and nitrites into nitric oxide [46]. Considering that the abundance of Lactobacillus and Bifidobacterium is increased in AD and PD patients, there may be higher nitric oxide concentrations in these patients, resulting in detrimental effects by the production of reactive oxygen species and reactive nitrogen species (such as superoxide and H2O2), thereby aggravating the disease. These pieces of evidence indicate that the gut microbiome plays a role in the oxidative stress in NDs, and may represent a promising therapeutic target for NDs.
Pathways by which the gut microbiome communicates with the brain in NDs
The complex interplay between the gut microbiome and the brain in NDs may occur through immunological, vagus nerve and circulatory pathways (Fig. 2).
Fig. 2 Routes by which microbes modulate neurodegenerative diseases. In the immunological pathway, gut microbe-derived products or metabolites (e.g., LPS) pass through the gut barrier and activate innate immune cells, primarily monocytes, and subsequently increase secretion of proinflammatory cytokines (TNF-α, IL-1β, IL-6, etc.) and reduce the phagocytic capacity of monocytes for amyloid proteins, leading to elevated neuroinflammation and amyloid aggregates in the brain. Gut dysbiosis also promotes the conversion of CD4+ T cells into proinflammatory phenotypes (Th1 and Th17), which secrete proinflammatory cytokines (IFN-γ, TNF-α, IL-1β, IL-17 A, etc.). These microbes can traverse the impaired blood-brain barrier and interact with microglia in the brain, exacerbating neuroinflammation. In the vagus nerve pathway, neurotransmitters and hormones secreted by enteroendocrine cells upon stimulation by the gut microbiome and its products can activate the vagus nerve. Amyloid-producing bacteria trigger gut amyloid accumulation, which is retrogradely transported to the brain via the vagus nerve. Gut microbe-derived extracellular vesicles can penetrate the brain through the vagus nerve and bloodstream, reducing BNDF expression in neurons and exacerbating neuroinflammation. In the circulatory pathway, microbes, their products, and neurotransmitters and hormones secreted by enteroendocrine cells can enter the peripheral circulation and cross the blood-brain barrier, leading to damage to neurons and microglia, reduced microglial phagocytic capacity, and increased neuroinflammation and amyloid aggregates in the brain. BDNF brain-derived neurotrophic factor, EC enteroendocrine cell, IFN-γ interferon-γ, IL interleukin, LPS lipopolysaccharide, Th T helper cell, TMA trimethylamine, TMAO trimethylamine-N‐oxide, TNF-α tumour necrosis factor-α |
Immunological pathway
The brain and the periphery, as well as the innate and adaptive immunity, are important modulators of neuronal health in NDs [47,48,49]. Senescence of immune cells and chronic inflammation are indicators of brain ageing and NDs [50]. Due to the increased oxidative stress and mitochondrial dysfunction, the microglia in brain or the peripheral monocytes become less efficient in the removal of disease-specific protein aggregates, such as Aβ in AD, α-synuclein in PD and huntingtin protein in HD, and induce excessive inflammation [3,48,50,51]. Importantly, the gut microbiome plays a role in the development and function of microglia and monocytes [52,53]. It was found that germ-free mice display altered cell proportions and immature phenotypes of microglia, indicating that gut microbiome is involved in the normal development of microglia [53,54]. The microglia in aged SPF mice display altered phenotypes and increased levels of oxidative stress compared to those in young SPF mice, while there is no such difference between young and aged germ-free mice. This result suggests that the gut microbiome regulates the ageing of microglia [55]. In addition to microglia, gut dysbiosis also influences the lifespan of monocytes, evidenced by the increased number of apoptotic Ly6Chigh monocytes in the peripheral [56,57]. Additionally, the products of gut microbiome (LPS, flagellin, etc.) in the blood can regulate the functions of trafficking monocytes [58]. In NDs, transplantation of the faecal microbiome from healthy donors has been shown to ameliorate microglial reactivity and functional impairments in both AD and PD mice, and decrease the levels of circulating blood inflammatory monocytes in AD mice [59].
Currently, many studies have revealed the role of peripheral T cells in the pathogenesis of NDs, although these diseases are not predominantly characterized by immune cell infiltration into the central nervous system as seen in conditions like multiple sclerosis or infections. T cells infiltrating into the brain may interact with microglia, aggravating neuroinflammation and contributing to the pathogenesis of NDs, such as AD and PD [60,61,62,63]. A recent study highlighted the essential role of peripheral activation of conventional CD4+ T cells by the gut microbiome in microglial maturation, proper synaptic pruning, and cognitive function in mice [64]. Oral pathogens Veillonella parvula and Streptococcus mutans can aggravate the motor deficits and neurodegeneration in MPTP-induced PD mice, which may be due to the alterations of gut microbiome, increased microglial activation and Th1 cell infiltration into the brain [65].
Vagus nerve pathway
The vagus nerve connects the gut’s muscular and mucosal layers with the brainstem. Notably, the vagus nerve is crucial for transmitting signals from the gut microbiome to the brain. An animal study found that FMT from aged mice or human donors into young mice impaired the hippocampus-dependent memory, while increasing the vagal ascending activity ameliorated this adverse effect [66]. This finding suggests that vagus nerve stimulation holds potential as a treatment for alleviating cognitive impairments associated with gut dysbiosis. Consistently, human data have revealed that vagus nerve stimulation is a possible therapy for AD and PD patients [67,68]. Stimulation of the vagus nerve can improve the cognitive functions and decrease the Aβ loads in the hippocampus of 6-month-old APP/PS1 transgenic mice by promoting microglial phagocytic activity towards Aβ [69]. Furthermore, it has been reported that neurotransmitters and gut hormones secreted by enteroendocrine cells induced by the gut microbiome can influence neuroinflammation and cognitive function through vagus nerve stimulation [70,71].
In AD and PD, Aβ and α-synuclein are deposited not only in the brain but also in the gut [72,73,74]. A variety of amyloid-producing bacteria in the gut can trigger amyloid accumulation, and these nonhuman amyloids with prion-like properties can undergo retrograde translocation to the brain via the enteric nerve and the vagus nerve [75,76,77]. Additionally, gut microbiome-derived extracellular vesicles can penetrate both intestinal epithelium and vascular endothelium, and enter host cells through endocytosis [78]. It has been found that the gut microbe-derived extracellular vesicles can enter the brain via blood and the vagus nerve, subsequently affecting cognitive function in mice [79]. These findings shed light on why full truncal vagotomy is associated with a reduced risk of PD [80,81].
The protective effects of vagus nerve stimulation and vagotomy on NDs appear to be a contradiction. We hypothesize that this could be explained that the vagus nerve serves as a conduit for not only beneficial signals but also potentially harmful substances. It is speculated that vagus nerve stimulation, in the condition of eradication of gut pathogens, might be an effective therapeutic approach for NDs.
Circulatory pathway
Microbe-derived products and metabolites play important roles in the gut microbiome-brain communication. In fact, the blood is not “sterile” even in healthy organisms, and it is speculated that gut is a major source of the microbes in blood [82]. Interestingly, it has been found that the microbiome profiles in blood are distinct between mild cognitive impairment or AD patients and healthy controls [83]. LPS, a natural ligand for Toll-like receptor 4 (TLR4), is a major surface membrane component of gram-negative bacteria. LPS can translocate into the blood and the brain through the impaired gut barrier and blood-brain barrier (BBB), subsequently activating TLR4 on microglia and exacerbating amyloid aggregation and progression of NDs [84,85,86]. Consistently, colocalization of LPS and Aβ plaques has been observed in the postmortem brain tissues of AD patients [87]. Moreover, many microbial metabolites can enter systemic circulation and directly influence brain functions [71]. For example, acetate, a SCFA, is increased in the blood of AD patients, and can reduce microglial phagocytosis of Aβ and accelerate disease progression in AD mice [85,88]. High levels of the gut microbial metabolite trimethylamine-N‐oxide (TMAO) in the blood have been found to exacerbate brain pathology associated with AD and PD and aggravate neuroinflammation in mouse models [89,90].
Altogether, the above evidence indicates that the gut bacteria and their products and metabolites communicate with the brain via immunological, vagus nerve and circulatory system pathways. Further studies are needed to detail the mechanisms involved in these processes. The gastrointestinal tract harbours a complex ecosystem, including microorganisms and their products and metabolites. We propose that the gut microbiome impacts NDs through these routes simultaneously, and modulation of the gut microbiome is a promising approach to targeting multiple key pathways involved in the pathogenesis of NDs.
Potential clinical approaches targeting the microbiome in NDs
The gut microbiome is a crucial modifier of ND risk, and targeting the gut microbiome can be a feasible approach to treating NDs. There are several factors and treatments that can reshape the gut microbiome, serving as potential therapies for NDs (Fig. 3).
Fig. 3 Potential strategies of gut microbiome-targeting therapies for neurodegenerative diseases. Diet (diet patterns and nutritional supplements), probiotics and prebiotics, microbial metabolites (supplementation of beneficial metabolites and elimination of harmful metabolites), antibacterials (antibiotics and bacteriophages) and faecal microbiome transplantation (traditional and synthetic microbiome transplantation) can all make the gut microbiome “healthy”, which prevents and alleviates neurodegenerative diseases. FMT faecal microbiome transplantation, IPA indole-3-propionic acid, MeDi Mediterranean, MIND Mediterranean-DASH Diet Intervention for Neurodegenerative Delay, PUFA polyunsaturated fatty acid, TMAO trimethylamine-N-oxide |
Diets
Diet is a significant determinant for the composition and function of the gut microbiome. It provides “fuel” for both hosts and microbes, and diet is also a crucial modifiable risk factor for NDs [91,92]. This interplay between diet and microbiome may partly explain why diet can influence the development of NDs.
Anti-inflammatory diets
Recent studies have found that proinflammatory diets reflected by higher dietary Inflammatory Index scores are associated with higher incidences of AD and PD [93,94,95]. Importantly, the overall inflammatory potential of the diet is related to the gut microbiome composition. Certain bacteria including Ruminococcus torques, Eubacterium nodatum, Acidaminococcus intestini and Clostridium leptum, are more abundant in pro-inflammatory diets, while Akkermansia muciniphila is enriched in anti-inflammatory diets [96].
Mediterranean (MeDi) diet and Mediterranean-DASH Diet Intervention for Neurodegenerative Delay (MIND) diet
MeDi diet and MIND diet emphasize the consumption of plant foods, seafood, poultry, olive oil and dairy products while limiting the intake of red meat and high-saturated-fat foods. Several studies have shown that these diets can lower the risks of AD and PD and alleviate disease symptoms [97,98,99,100,101]. A systematic review revealed that the MeDi diet can increase the relative abundance of certain bacteria, such as Christensenellaceae, Bilophila, and Escherichia/Shigella, in both AD and PD patients, although the pathologies of the two diseases are different [102].
Ketogenic diet
The ketogenic diet is a high-fat, low-carbohydrate and adequate-protein diet. It has been applied in various neurological diseases, including epilepsy, AD and PD. Randomized trials have suggested that the ketogenic diet can improve cognitive function and quality of life in AD patients, as well as the motor and nonmotor symptoms in PD [103,104]. Evidence from seizure studies highlights the vital role of the gut microbiome in the neuroprotective effects of a ketogenic diet. It has been reported that the germ-free mice or mice treated with antibiotics are resistant to the ketogenic diet-mediated seizure protection, and transplantation of the ketogenic diet gut microbiome can confer seizure protection to mice via reducing systemic gamma-glutamylated amino acids and increasing hippocampal γ-aminobutyric acid (GABA)/glutamate levels [105].
Nutritional supplements
Dietary choline A cohort study in eastern Finland suggested that higher total choline intake is associated with better cognitive performance [106]. However, recent results from the Framingham Heart Study indicate that high choline intake may increase the risks of dementia and AD, although it did not reach statistical significance [107]. Choline is a primary source of trimethylamine (TMA), a gut microbe-derived metabolite that can be converted to TMAO in the liver. TMAO is a risk factor for age-related cognitive decline and dementia [71]. It is speculated that the composition and function of the gut microbiome may determine whether dietary choline will be converted to TMAO. Further studies are needed to explore the mechanisms underlying this relationship and determine the optimal amount of dietary choline intake.
Vitamins Studies have suggested that vitamins A, B, D and E have neuroprotective effects against AD and PD [108,109,110,111]. Importantly, the gut microbiome is involved in vitamin metabolism [112]. Approximately 30% of a person’s daily supply of B group vitamins is from synthesis by certain strains of gut microorganisms [113,114]. Furthermore, vitamins can directly or indirectly modulate the gut microbiome [115]. A cross-sectional study showed that serum levels of 1,25(OH)2D can explain 5% and 2% of variances in α-diversity and β-diversity of the gut microbiome, respectively [116]. Vitamin A deficiency exacerbates learning and memory impairments, increases the Aβ burden in the brain and gut, and downregulates brain-derived neurotrophic factor and GABA receptors in the cortex. These effects are associated with the altered α- and β-diversity of the gut microbiome and a decreased abundance of Lactobacillus in AD (APP/PS1) mice [117]. These findings highlight the vital role of the bidirectional interactions between vitamins and the gut microbiome in NDs.
Polyunsaturated fatty acids (PUFAs) Observational and interventional studies have shown that higher levels of PUFAs and long-term PUFA supplementation are associated with a slower cognitive decline in AD patients, as well as reduced motor dysfunctions and a lower incidence of PD [118,119,120,121,122]. Several clinical trials have demonstrated that omega-3 PUFA supplementation can increase the abundance of Bacteroidetes and butyrate-producing bacteria belonging to the Lachnospiraceae family [123,124,125]. Importantly, these two taxa are significantly associated with disease severity of NDs [123,124,125].
In summary, diet plays a crucial role in the onset and development of NDs, and remodelling of the gut microbiome may be one of the possible explanations for this effect. The interactions among diet, gut microbiome and NDs are complex. The current evidence is mainly based on observational results, and further randomized clinical trials (RCTs) are needed to explore their relationships.
Probiotics and prebiotics
Probiotics and prebiotics are well-known treatments for modulating the gut microbiome and improving human health. Their therapeutic potential in NDs is discussed below.
Probiotics
Lactobacillus and Bifidobacterium. Lactobacillus and Bifidobacterium are the most common probiotics and have been widely included in yoghurt and in pharmaceuticals. Tamtaji et al. identified that probiotics (Lactobacillus acidophilus, Bifidobacterium bifidum, and Bifidobacterium longum, 2 × 109 CFU/day) combined with selenium supplementation significantly enhanced cognitive function compared to selenium or placebo alone in AD patients [126]. Administration of probiotic Lactobacillus and Bifidobacterium strains alleviated both constipation symptoms and motor symptoms in PD patients [127,128]. However, a meta-analysis that included trials investigating the effects of probiotics, mainly Lactobacillus and Bifidobacterium, did not find any beneficial effects on cognitive function in diagnosed AD patients [129]. The increased abundance of Lactobacillus and Bifidobacterium in patients with AD and PD may raise doubts on their potential beneficial effects on NDs. It is important to note that different species within the same genus might have distinct effects. To gain a better understanding, high-quality metagenomic data with strain-level resolution will be instrumental in identifying the specific species of Lactobacillus and Bifidobacterium that exhibit altered abundance among individuals with NDs. Consequently, further research is necessary to confirm the applicability of Lactobacillus and Bifidobacterium in NDs.
Clostridium butyricum. In addition to these common probiotics, there is a need to explore novel probiotics targeting NDs. Clostridium butyricum is a notable probiotic that can ferment carbohydrates into butyric acid and has excellent protective effects against pathogenic microorganisms [130]. An animal study showed that a 4-week treatment with Clostridium butyricum (5 × 108 CFU/day) effectively protected against cognitive impairment and amyloid pathology by reducing microglia-mediated neuroinflammation in an AD (APP/PS1) mouse model [131]. Furthermore, Clostridium butyricum treatment reverses the abnormal gut microbiome and restores the level of butyrate [131]. Clostridium butyricum treatment also ameliorates motor deficits, dopaminergic neuronal loss, synaptic dysfunction and microglial activation in mice with MPTP-induced PD, and these effects are associated with restoration of the gut microbiome and reduced levels of colonic glucagon-like peptide-1 (GLP-1), colonic G-protein-coupled receptor 41/42 and cerebral GLP-1 receptor [132].
Akkermansia muciniphila. Ageing is the major risk factor for NDs. Studies in ageing and rejuvenation animal models have shown that Akkermansia and the butyrate biosynthesis pathway are crucial in ageing [133]. Preclinical studies showed that Akkermansia muciniphila can effectively halt the progression of NDs [134,135,136]. It significantly reduces the fasting blood glucose and serum diamine oxidase levels, ameliorates the reduction of colonic mucus cells, and further decreases the levels of Aβ40/42 in the cerebral cortex and ameliorates cognitive deficits in APP/PS1 AD mice [134]. Another study revealed that Akkermansia muciniphila treatment ameliorates cognitive deficits, Aβ deposition in the brain, and bone loss in AlCl3/D-galactose injection-mediated AD rats [135]. Moreover, it increases the abundance of SCFA-producing or neurotransmitter-producing gut microbiome like Blautia, Staphylococcus, and Lactococcus [135]. Akkermansia muciniphila treatment also leads to accumulation of Akkermansia muciniphila-associated nicotinamide in the central nervous system, thereby improving motor symptoms and gene expression patterns in the spinal cord of ALS (Sod1-Tg) mice [136]. However, other studies suggest that Akkermansia is a mucin-degrading genus that is increased in faecal samples from PD patients and may exacerbate PD progression [137,138].
More high-quality clinical trials are needed to identify the neuroprotective effects of these specific strains of microorganisms in NDs. The inconsistent and unstable results imply that (1) distinct disease models with different gut microbiome compositions may account for the diverse effects of probiotics; and (2) focusing on the changes in one or two taxa is not enough, as the complex interactions among microbes need to be considered.
Prebiotics
Numerous preclinical studies have suggested the potential of prebiotics as an adjuvant treatment for NDs. Intake of soluble fibre for 2 months significantly alleviated astrocyte activation and improved cognitive function in 6-month-old male AD (APP/PS1) mice [139]. These effects depended on the modulation of butyrate/propionate production by gut microbiome, and were eliminated in antibiotic-treated mice, indicating that the neuroprotective effects of soluble fibre depend on the gut microbiome [139]. A 16-week fibre-rich diet ameliorated motor function and α-synuclein aggregation in the substantia nigra of PD (α-synuclein-overexpressing) mice by reversing pathogenic microglial states [140]. The high-fibre diet also improved the cognitive and affective functions as well as the gastrointestinal function of HD mice by altering the gut microbiome profiles [141]. A longitudinal human study showed that higher dietary fructan intake is associated with a lower incidence of AD in the elderly [142]. Furthermore, a diet rich in insoluble fibre significantly improved motor function and constipation symptoms, and increased the plasma level of L-DOPA, in PD patients with constipation [143]. Considering the diversity of the gut microbiome in patients of different sexes, ages and diseases, investigating which prebiotics provide “food” for specific microbes will provide guidance for future applications of prebiotics in specific populations.
Gut microbiome-derived metabolites
SCFAs
Microbiome-derived SCFAs, such as acetate, propionate, and butyrate, are small organic compounds primarily produced from anaerobic fermentation of dietary fibres in the gut and are able to translocate from the gut to the circulation and across the BBB [88]. Sodium butyrate has been observed to enhance the long-term potentiation and depotentiation, and promote the development of dendritic spines and synapse-associated proteins in 5×FAD mice [144]. Wang et al. demonstrated that sodium butyrate has the potential to ameliorate cognitive deficits induced by Aβ25-35 injection in mice, which may be attributed to its ability to promote the differentiation of astrocytes towards the A2-neuron-protective subtype [145]. However, the roles of acetate and propionate in AD are controversial. Liu et al. found that microglial activation and cognitive impairment were attenuated by acetate in APP/PS1 mice [146], while another study demonstrated that acetate induced a proinflammatory phenotype in microglia and aggravated Aβ deposition [88]. A recent study showed that propionate treatment suppressed the levels of inducible nitric oxide synthase and pro-inflammatory cytokines and restored synaptic plasticity and cognitive function in Aβ1−42-induced AD mice [147]. However, a study in a three-city population-based cohort found that higher serum levels of propionate are associated with increased odds of cognitive decline [148].
In an MPTP-induced PD mouse model, sodium butyrate treatment led to worsening of motor deficits, dopaminergic neuronal loss and glia-mediated neuroinflammation via exacerbating pro-inflammatory cytokine expression and nitric oxide production [149]. However, a study by Sampson et al. revealed that an SCFA mixture caused microglial activation and motor deficits in germ-free α-synuclein overexpressing mice [35]. For ALS, butyrate administration may be beneficial, as it can restore gut microbiome homeostasis, maintain gut integrity, and prolong lifespan in G93A transgenic mouse model of ALS [150]. Overall, the role of SCFAs in NDs is rather complex and may depend on their dosage. Further clinical trials and in-depth basic research are needed to elucidate their roles and mechanisms of action in NDs.
Secondary bile acids
Secondary bile acids are gut microbiome-derived molecules that may directly affect NDs. AD individuals show significantly increased serum levels of secondary bile acids, such as deoxycholic acid and its glycine- and taurine-conjugated forms, compared to controls [151]. Higher deoxycholic acid : cholic acid ratio and increased levels of conjugated bile acids (glycodeoxycholic acid, glycolithocholic acid and taurolithocholic acid) are strongly correlated with cognitive decline [151]. In PD patients, the plasma levels of deoxycholic acid and glycodeoxycholic acid are significantly higher than those in controls, and the plasma level of glycodeoxycholic acid is also associated with positive PD status [152]. Furthermore, the plasma level of deoxycholic acid correlates with the relative abundance of Lachnoclostridium sp. An14 and Anaerotignum lactatifermentans of the family Lachnospiraceae, and the glycodeoxycholic acid concentration correlates with the pro-inflammatory bacterial genera Alistipes and Bacteroides [152]. The gut microbiome-derived secondary bile acids exert their effects by binding to their receptors, such as farnesoid X receptor, liver X receptor α and β, and sphingosine-1-phosphate receptor 2 [153]. Further investigations of the roles of bile acid receptors may lead to novel therapeutic approaches to treating NDs.
TMAO
TMAO has been linked to cell senescence and ND pathogenesis [154,155]. Inhibiting TMAO formation with 3,3-dimethyl-1-butanol has been shown to ameliorate cognitive dysfunction in APP/PS1 transgenic mice [71,156,157]. This suggests that therapeutics aimed at eliminating gut microbiome-derived deleterious metabolites hold promise for treatment of NDs.
Other metabolites
Indole-3-propionic acid (IPA) is a gut microbiota metabolite synthesized from tryptophan. Preclinical studies revealed that IPA can improve the intestinal barrier, restore gut microbiome homeostasis and inhibit Aβ fibril formation, suggesting its potential use for the treatment of AD. S-equol, equol, and phenyl-γ‐valerolactones are also promising microbial metabolites for treating NDs [158,159,160,161,162,163].
Antibacterials
Antibiotics
Antibiotics are widely used to treat infections caused by pathogenic microorganisms, and they also have a significant impact on the gut microbiome. There is growing evidence supporting the “infectious hypothesis” of AD [164,165]. Hospitalisation for any infectious disease has been found to be associated with a higher risk of AD [164], which implies that the use of antibiotics might be a potential treatment for AD. A study showed that early postnatal antibiotic cocktails (postnatal day 14-21) led to a long-term alteration of gut microbiome composition in the form of increased abundance of Lachnospiraceae and S24-7 and a reduction of Aβ deposition in the brains of aged APP/PS1 mice, with elevated numbers of Foxp3+ T regulatory cells in blood and brain [166]. However, administration of broad-spectrum antibiotic cocktails from early adolescence to adulthood exacerbated spatial memory impairment in adult male mice after Aβ1−42 microinjection, and decreased TNF-α and IL-6 levels in the brain [167]. These findings imply that the effects of antibiotics can vary depending on the timing, duration, and pharmacological actions of the antibiotics. A clinical trial revealed that both short-term and long-term treatment with D-cycloserine can improve the cognitive functions of AD patients [168]. However, retrospective studies have indicated that broad- and narrow-spectrum antibiotics increase the risks of overall dementia and AD [169,170]. A multicentre RCT revealed that doxycycline or rifampin treatment resulted in significant deterioration in SADAS-cog score in mild and moderate AD patients [171].
Antibiotics have also been found to significantly improve motor dysfunction and alleviate neuroinflammation by increasing the relative abundance of Akkermansia and Lachnospiraceae and SCFA levels in the faeces of MPTP-induced and transgenic PD mouse models [172,173,174]. A 12-month study found that creatine and minocycline can delay the disease progression in PD patients [175]. However, a nationwide case-control study in Finland showed a positive association between exposure to certain antibiotics (including antianaerobics, tetracyclines, sulfonamides and trimethoprim) and an increased incidence of PD [176]. A nested case-control study conducted in Sweden revealed that the use of any antibiotics is associated with a higher risk of ALS, particularly for those who have received more than two prescriptions of beta-lactamase sensitive penicillin [177].
While there is promising evidence from preclinical studies about the potential role of antibiotics in preventing NDs, more research is needed to translate these findings into effective treatments in patients. The gut microbiome is a complex ecosystem with many microorganisms, and it is challenging to inhibit or promote the growth of specific microbes. Moreover, the widespread use of antibiotics can lead to the emergence of drug-resistant bacteria. Therefore, it is necessary to explore solutions to address the limitations of antibiotics.
Bacteriophages
Currently, nonbacterial constituents of the microbiome, such as viruses, have received much attention. Bacteriophages are viruses that infect bacteria and have been widely used as antibacterial agents to modulate the gut microbiome and treat diseases for over 100 years [178,179]. A recent preclinical study revealed that Ruminococcaceae and its metabolite isoamylamine are highly enriched in aged mice and elderly people, contributing to neuroinflammation and age-related cognitive decline [180]. Isoamylamine can aggravate apoptosis of microglia by recruiting the transcriptional regulator p53 to the S100A8 promoter region, leading to microglial dysfunction [180]. Interestingly, the presence of Myoviridae bacteriophage, which targets Ruminococcaceae, is significantly reduced in the gut of aged mice [180]. Oral administration of Myoviridae bacteriophage dramatically decreases the level of isoamylamine in the gut and reduces neuroinflammation [180]. These findings suggest that bacteriophages may be powerful tools for modulating the gut microbiome. More preclinical and clinical studies are needed to determine the therapeutic potential of bacteriophages for NDs.
FMT and synthetic microbiome transplantation
FMT
FMT is an emerging potent method for restoring the gut ecosystem. The species-rich microbiomes as well as their products and metabolites from healthy donors can increase the microbial diversity, alter the production of metabolites from certain microbes and the host, and alter the host immune response [181]. Studies in mouse models have shown that transplantation of the faecal microbiome from healthy (wild-type) mice with antibiotic cocktail pretreatment can reverse the abnormalities in the colonic expression of genes related to gut macrophage activity and the circulating inflammatory monocytes, and subsequently reduce brain Aβ burden and phosphorylation of tau protein and improve the cognitive function of AD (ADLPAPT) mice [59,182]. Additionally, another study demonstrated that FMT from young or healthy (wild-type) mice, in the absence of antibiotic administration, can also ameliorate Aβ plaques and cognitive impairments in 5×FAD mice [183]. In rotenone-induced PD mice, motor deficits were ameliorated two weeks after FMT from healthy mice, without pre-antibiotic treatment. These protective effects might be attributed to the reductions in LPS and the TLR4/myeloid differentiation primary response gene 88/ nuclear factor-kappa B signalling pathway in the colon, serum and brain, along with improved BBB integrity [184]. A few clinical cases or trials investigating the effects of FMT in AD and PD patients have shown promising results. For instance, at 48 h after discontinuation of antibiotic prescriptions (vancomycin and metronidazole), dementia patients with cognitive decline and Clostridioides difficile infection received FMT via colonoscopy [185]. They showed enhanced cognitive function one month after receiving FMT from healthy donors, compared to the baseline [185]. Recently, Cheng et al. enrolled 54 PD patients, with 27 receiving oral FMT capsules and the remaining 27 receiving placebo capsules without antibiotics pretreatment [186]. Patients who underwent oral FMT showed improvement in PD-related autonomic symptoms, gastrointestinal disorders and the complexity of the microecological system at three months post-FMT [186]. Another study included 15 PD patients, 10 receiving colonic FMT and 5 nasointestinal FMT [187]. FMT relieved the motor deficits, improved the quality of life and sleep, and relieved anxiety and depression at 1 and 3 months post-FMT, although 5 of these 15 patients reported adverse events including diarrhoea, flatulence and abdominal pain [187]. In addition, the colonic FMT was more effective than the nasointestinal FMT and maintained the efficacy for a longer time [187].
While FMT shows promise as a therapeutic approach for AD and PD, there are still many questions to be answered. (1) Of the various FMT approaches, including upper gastrointestinal (i.e., capsule delivery, nasointestinal tubes) and lower gastrointestinal routes (i.e., retention enema, sigmoidoscopy or colonoscopy), which one is more suitable for NDs [188]? (2) What are the optimal duration and timing of FMT for NDs? (3) It is unknown whether antibiotic pretreatment is necessary. (4) The quality of donor faeces is a determinant for the effectiveness of FMT, which limits the standard implementation of FMT in large populations.
Synthetic microbiome transplantation
Although traditional FMT is relatively safe, the donor faecal microbiome is like a “black box” that contains many unknown ingredients, such as bacteria, yeasts, parasites and viruses, which can be detrimental for recipients. Recently, researchers have proposed the “synthetic microbiome” for transplantation, which has a well-defined composition of bacteria. Cheng et al. designed a community of 104 bacterial species called “hCom2”. Mice colonized by the hCom2 had a similar phenotype as those colonized by the human faecal community [189]. This concept suggests that designing a synthetic microbiome mimicking the gut microbiome of healthy individuals and adding specific probiotics that are beneficial for patients with NDs may be a promising strategy to overcome the shortcomings of traditional FMT in treating NDs.
Perspectives and conclusion
Intriguing preclinical and clinical evidence reveals the crucial role of the gut microbiome in the development of NDs. Modulation of the gut microbiome has emerged as a potential therapeutic option outside of the brain. However, there is a long way to go from preclinical or observational evidence to clinical application.
Although there is a general consensus that the gut microbiome is significantly altered in NDs and can modify the risks and progression of NDs, much remains unknown. Defining the characteristics of the gut microbiome in NDs and identifying precise markers to differentiate between ND patients and healthy individuals is paramount. High-quality metagenomic data with strain-level resolution and metabolomics data across large longitudinal cohort studies will help address these challenges. Moreover, clear mechanistic details concerning the routes through which gut bacteria and their products impact the brain are currently unknown. Further research into how gut microbes modulate immune cells, regulate amyloid deposition and tau aggregation in the gut and the brain, and pass through barriers may lead to development of drugs and therapeutic strategies that target the gut microbiome.
In the present review, we discussed various potential clinical approaches aimed at targeting the gut microbiome in NDs. Among these, probiotics, antibacterials and FMT directly modify the composition of the gut microbiome. In contrast, dietary patterns, nutritional supplements, and prebiotics supply “nutritional substances” and create a modified living environment for the gut microbiome, thereby indirectly regulating its profile. Additionally, the supplementation of beneficial metabolites and the elimination of harmful metabolites focus on the “secondary products” of the gut microbiome. All of these gut microbiome-targeted strategies have proven effective for NDs. However, the mechanisms underlying these promising therapeutic approaches for NDs remain largely unknown, necessitating further in-depth exploration.
The host-microbiome interactions in NDs are complex. The gut microbial DNA expression and pathways are regulated by molecules produced by the host gut epithelial cells [190]. Studies have identified APOE ε4 and rs429358 alleles as risk factors for AD, which show a positive correlation with the abundance of pathogenic Proteobacteria and the proinflammatory genus Collinsella, respectively [191,192]. In addition, the A53T transgenic monkeys show α-synuclein aggregation in the gut, a higher degree of diversity of the gut microbiome, and elevated abundance of Sybergistetes, Akkermansia, and Eggerthella lenta [193]. Building on the above evidence regarding the potential of gut microbiome modulation to halt the progression of NDs, it is speculated that targeting the gut microbiome could be an effective therapeutic approach for patients susceptible to NDs due to genetic factors. Moreover, gut microbiome treatments should be tailored based on the unique microbial alterations observed in different ND patients.
Considering that the gut microbiome ecosystem is complex and has variability among individuals and that the equilibrium of the ecosystem is maintained by microbial diversity and stability as well as microbe-microbe and host-microbe interactions [194], the final goal of microbial modulation is the maintenance of equilibrium of the gut microbiome ecosystem based on an individual’s microbiome. Standardization and industrialization of methods for engineered probiotics, gut-derived metabolite analogues, synthetic human gut microbiomes for FMT, etc., are urgently needed. The gut microbiome is a promising approach for understanding and treating NDs, so future studies should explore the in-depth mechanisms involved in the gut microbiome-brain axis to identify the optimal ways to maintain and restore the equilibrium of the gut microbiome ecosystem.
Abbreviations
Aβ:Amyloid-β
AD:Alzheimer’s disease
ALS:Amyotrophic lateral sclerosis
FMT:Faecal microbiome transplantation
GABA:γ-Aminobutyric acid
GLP-1:Glucagon-like peptide-1
HD:Huntington’s disease
HDGECs:HD gene expansion carriers
IL:Interleukin
IPA:Indole-3-propionic acid
LPS:Lipopolysaccharide
MeDi:Mediterranean
MIND:Mediterranean-DASH diet intervention for neurodegenerative delay
ND:Neurodegenerative disease
PUFA:Polyunsaturated fatty acid
RBD:REM sleep behaviour disorder
RBD-FDR:First-degree relatives of RBD
SCFA:Short-chain fatty acid
SPF:Specific pathogen-free
TLR4:Toll-like receptor 4
TMA:Trimethylamine
TMAO:Trimethylamine-N‐oxide
PD:Parkinson’s disease
Acknowledgements
Not applicable.
Author contributions
YW contributed to the conception and design of the review. YM and XL written the first draft of the manuscript and created the figures. YW and JY critically revised the manuscript. All authors approved the submitted version.
Funding
This review was supported by the National Natural Science Foundation of China (92249305) and the Special Funding for Chongqing Postdoctoral Research Project.
Availability of data and materials
Not applicable.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
